Charles River Associates (CRA) Strengthens Capabilities In Life Sciences
River Associates (NASDAQ: CRAI), a worldwide leader in providing
economic, and financial consulting services, today announced that
Aroy has joined the firm as a vice president in the...
Charles River Associates (NASDAQ: CRAI), a worldwide leader in providing management, economic, and financial consulting services, today announced that Jeffrey Aroy has joined the firm as a vice president in the Life Sciences Practice based in Boston. Mr. Aroy has more than 20 years of experience as a consultant and executive in the life sciences industry. “Jeffrey Aroy’s knowledge of the clinical and commercial pillars of the life sciences industry is an excellent complement to CRA’s life sciences offering and we are pleased to welcome him to CRA,” said CRA's President and Chief Executive Officer Paul Maleh. “Jeff has direct industry experience, as a founder and leader of multi-million dollar life sciences companies, as well as an extensive consulting background where he has advised on corporate strategy issues and strategic marketing concerns throughout the product life cycle. His comprehensive knowledge of the industry dovetails with the expertise clients seek from CRA.” Mr. Aroy’s consulting practice focuses on growth strategies in life sciences, with emphases on product launch, portfolio prioritization, companion diagnostic, and emerging markets strategies. He has deep expertise in multiple therapeutic areas and has worked across industry sectors covering large pharma, biotech, medical devices, and diagnostics. Mr. Aroy joins CRA from Leerink Swann where he was a Senior Managing Director and business unit head of Leerink’s professional consulting practice. Mr. Aroy’s responsibilities included developing and leading some of Leerink’s significant relationships with large life sciences companies. In addition, Mr. Aroy has executive experience as a leader of two growth-stage diagnostics companies, both of which were acquired for a combined half billion dollars. As General Manager at Berkeley HeartLab, he managed a $60 million business focused on advanced cardiovascular products and was responsible for sales, marketing, and establishing a network of clinics, among other areas. As Chief Operating Officer of Cholestech, a point-of-care cardiovascular testing company, Mr. Aroy drove growth by forming novel partnerships with pharmaceutical companies to help increase diagnosis and treatment of heart disease.
Shares of CRA International (Nasdaq:CRAI) have taken a tremendous swing upward. The stock is trading at $24.92 as of 11:21 a.m. ET, 23.4% above Wednesday's closing price of $20.19. Volume is at 20,984, 0.5 times the daily average of 40,100.
Shares of CRA International (Nasdaq:CRAI) were gapping down Monday morning with an open price 14.3% lower than Friday's closing price. The stock closed at $19.87 yesterday and opened today's trading at $17.02.